Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease

Nikolaos Tzoumas, Tariq E. Farrah, Neeraj Dhaun, David J. Webb

Research output: Contribution to journalArticlepeer-review

Abstract

PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues through the inhibition of cGMP degradation. Although these agents were originally developed for the treatment of hypertension and angina, unanticipated side effects led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial hypertension. In the last decade, accumulating evidence suggests that PDE5Is may confer a wider range of clinical benefits than was previously recognised. This has led to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in conditions such as hypertension, myocardial infarction, stroke, peripheral arterial disease, chronic kidney disease and diabetes mellitus. Here, we review the pharmacological properties and established licensed uses of this class of drug, along with emerging therapeutic developments and possible future indications.
Original languageEnglish
JournalBritish Journal of Pharmacology
Early online date12 Nov 2019
DOIs
Publication statusE-pub ahead of print - 12 Nov 2019

Fingerprint Dive into the research topics of 'Established and emerging therapeutic uses of phosphodiesterase type 5 inhibitors in cardiovascular disease'. Together they form a unique fingerprint.

Cite this